.jetcityimage/iStock Editorial via Getty Images Morgan Stanley has opted for Eli Lilly (NYSE: LLY) as its own leading biopharma selection for 2025 as well as rated an additional nine titles in the space as overweight. The expenditure banking company said in a note that it continues to strongly believe “diabesity is actually set to come to be.